UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Tickers reports and analysis
Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback.
Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June…
Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT.
After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests.
Primary endp
Spectral AI is one of those very small companies where the story looks simple on the surface and much more complicated once you open the hood. The company is trying to bring its DeepView burn-imaging platform through the FDA while using non-dilutive government support to fund part of the journey. The setup is interesting because it combines a real clinical problem, a potentially differentiated imaging workflow, and a government countermeasure angle. The catch is that this is still a micro-cap name with execution risk, regulatory risk, and financing risk that cannot be ignored.
This article compares five U.S.-listed energy names below $2 billion in market value that could benefit, directly or indirectly, from a stronger oil tape, firmer field activity, or renewed investor appetite for smaller-cap energy exposure: ProPetro (PUMP), VAALCO Energy (EGY), Ranger Energy Services (RNGR), Geospace Technologies (GEOS) and KLX Energy Services (KLXE).
Taxing unrealised gains: why the Dutch “experiment” is a red line for investors A closer look at the Actual Return Box 3 proposal in the Netherlands, why a 36% tax on unrealised portfolio gains is structurally toxic, and what this…
Focus on factual developments of the last few days (Strait of Hormuz, tankers at anchor, oil spike) and on a sector-based watchlist – not on trying to predict the endgame of the conf
An editorial look at what the new Iran–Israel–US conflict could mean for global power balances, for oil and shipping routes, and for the sectors and individual stocks that tend to benefit or suffer when the Middle East becomes the epicentre of risk.
EN
IT
Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm.
Ten US-listed small- and mid-cap biotech stocks with key H2 2026 catalysts, including PDUFA dates, FDA advisory committees and pivotal Phase 3 readouts. Exact dates are separated from company-guided windows; the original H1 2026 analysis remains available as a historical archive.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB).
Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period.
Deep dive on Neumora Therapeutics (NMRA): navacaprant reset, NMRA-511 Alzheimer’s agitation data, M4 franchise and a 2026–2027 catalyst map for biotech run-up traders. Educational only, not investment advice.
The FDA has approved an extension of the indicated duration of Nexplanon (etonogestrel implant) up to 5 years for the prevention of pregnancy, versus the previous 3-year label. Nexplanon is the flagship long-acting reversible contraception (LARC) product of Organon and one of the core pillars of its Women’s Health division.
SIDU, ASTS, LUNR, ONDS and PL are not just “hot tickers”. Their satellites, landers, drones and imaging constellations are becoming building blocks of a Western answer to China’s dual-use space programs, Russia’s drone war and a world where infrastructure and data are contested every single day.